90213-66-4

Basic information

• Product Name: 2,4-DICHLORO-7H-PYRROLO2,3-DPYRIMIDINE
• Synonyms: 2,4-DICHLORO-7H-PYRROLO2,3-DPYRIMIDINE;2,6-Dichloro-7-deazapurine;2,6-dichloro-7-deazapurin ;2,4-DICHLORO-7H-PYROLO-[2,3-D]PYRIMIDINE;4,6-DICHLORO PURINE;2,4-Dichloro-1H-pyrrolo[2,3-d]pyrimidine;2,4-Dichloro-7H-pyrrolo[2...;7H-Pyrrolo[2,3-d]pyriMidine, 2,4-dichloro-
• CAS NO: 90213-66-4
• Molecular Formula: C₆H₃Cl₂N₃
• Molecular Weight: 188.01
• Product Categories: Nucleotides and Nucleosides;CHIRAL CHEMICALS;Bases & Related Reagents;Intermediates;Nucleotides;Heterocycle-Pyrimidine series
• Mol File: 90213-66-4.mol
• Article Data: 21

Chemical Properties

• Melting Point: 247-250°C
• Boiling Point: 312oC at 760 mmHg
• Flash Point: 142.5oC
• Appearance: /Solid
• Density: 1.675 g/cm³
• Vapor Pressure: 0.0185mmHg at 25°C
• Refractive Index: 1.805
• Storage Temp.: Refrigerator
• Solubility: Acetone (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 9.18±0.20(Predicted)
• Water Solubility: Soluble in DMSO, ethyl acetate and methanol. Slightly soluble in water.
• CAS DataBase Reference: 2,4-DICHLORO-7H-PYRROLO2,3-DPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-7H-PYRROLO2,3-DPYRIMIDINE(90213-66-4)
• EPA Substance Registry System: 2,4-DICHLORO-7H-PYRROLO2,3-DPYRIMIDINE(90213-66-4)

Safety Data

• Hazard Codes: T
• Statements: 25-36-36/37/38-22
• Safety Statements: 26-45-28-36
• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 90213-66-4(Hazardous Substances Data)

Usage

Chemical Properties

Crystalline Solid

Uses

It is used as a pharmaceutical intermediate.

InChI:InChI=1/C5H2Cl2N4/c6-4-3-5(7,10-1-8-3)11-2-9-4/h1-2H

Upstream product

• 39929-79-8 7-deazaxanthine 
• 39929-79-8 pyrrolo<2,3-d>pyrimidin-2,4-dione 
• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 

Downstream Products

• 91713-42-7 2,4-Dichlor-7-<2-desoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl>-7H-pyrrolo-<2,3-d>pyrimidin 
• 1053228-30-0 2,4-dichloro-7-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine 
• 1053228-31-1 2,4,5-trichloro-7-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 900789-14-2 5-bromo-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 
• 1053228-29-7 2,4-dichloro-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine 
• 1053228-28-6 2,4,5-trichloro-7H-pyrrolo [2,3-d] pyrimidine 
• 1334106-79-4 2-chloro-4-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 135-70-6 p-quaterphenyl 
• 1236078-14-0 C₃₀H₂₁N₃ 
• 1334106-87-4 2-(4-ethoxyphenyl)-4-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1334106-88-5 4-[2-(4-ethoxyphenyl)-4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzonitrile 
• 1334106-89-6 4-[2-(biphenyl-4-yl)-4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzonitrile 
• 1334106-90-9 2-(biphenyl-4-yl)-7-(4-methoxyphenyl)-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine 
• 1334106-91-0 2-(4-ethoxyphenyl)-4-(4-methoxyphenyl)-7-phenyl-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents

Focal adhesion kinase (FAK) is a ubiquitous intracellular non-receptor tyrosine kinase, which is involved in multiple cellular functions, including cell adhesion, migration, invasion, survival, and angiogenesis. In this study, a series of 7H-pyrrolo[2,3-d

Synthesis method of tofacitinib citrate

The invention relates to the technical field of medicinal chemistry, and discloses a synthesis method of tofacitinib citrate. The method comprises 1) preparing 2,4-dihydroxy pyrrolopyrimidine: adding4-aminouracil and anhydrous sodium acetate into water (in a molar ratio of (1: 3)-(1: 5)), heating to 60-80 DEG C, slowly adding a 2-chloroacetaldehyde aqueous solution having a concentration of 40%,stirring to react for 4-6 hours, cooling to room temperature, filtering, washing a solid with water, and drying under reduced pressure to obtain 2,4-dihydroxy pyrrolopyrimidine. According to the synthesis method of tofacitinib citrate, through two times of impurity removal, the purity of the produced tofacitinib citrate finished product is higher, subsequent purification is not needed, the synthesis time is short, the process is simple, the method is suitable for factory production, the production time of the tofacitinib citrate finished product can be saved, the production efficiency of the tofacitinib citrate finished product is improved, and the tofacitinib citrate is more convenient to use.

Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient

The present invention relates to a conjugated pyrimidine derivative, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating Bruton′s tyrosine kinase activity-related diseases containing the same as an active ingredient. The conjugated pyrimidine derivative according to the present invention is excellent in the ability to inhibit the activity of Bruton′s tyrosine kinase or TMD80, and thus can be usefully used for prevention or treatment of diseases related to Bruton′s tyrosine kinase activity, particularly cancer or autoimmune diseases.COPYRIGHT KIPO 2019